In advanced pancreatic cancers treated by gemcitabine, SMAD4 loss had no impact on OS (HR 1.008; p = 0.656) but was associated with a prolonged PFS (HR 1.565, p = 0.038) [70]. This evidence concerns the gene SMAD4 and pancreatic neoplasm.